Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The DUTHY Trial: Durvalumab Plus Tremelimumab in Advanced Thyroid Carcinoma
NCT03753919Phase 2Terminated
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Apr 2019
- Primary completion
- Nov 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tremelimumab in thyroid carcinoma (TC), sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoints: Progression-free Survival Rate at 6 Months and Overall Survival Rate at 6 Months. Started Apr 2019; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
thyroid carcinoma (TC)
Beyond the preview
Go deeper on NCT03753919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03753919.